Not available
Quote | Lipocine Inc. (NASDAQ:LPCN)
Last: | $7.29 |
---|---|
Change Percent: | -0.51% |
Open: | $7.87 |
Close: | $7.29 |
High: | $7.9094 |
Low: | $7.105 |
Volume: | 30,288 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Lipocine Inc. (NASDAQ:LPCN)
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Message Board Posts | Lipocine Inc. (NASDAQ:LPCN)
Subject | By | Source | When |
---|---|---|---|
$LPCN short squeeze signal | RunninRobert | investorshub | 05/12/2023 7:26:37 AM |
Bottom was in on the eighth | Triple nickle | investorshub | 05/11/2023 4:27:09 PM |
Added | Triple nickle | investorshub | 05/11/2023 4:25:38 PM |
Time for this to show some returns | gi197845 | investorshub | 05/11/2023 4:04:56 AM |
$LPCN Found an interesting article | gi197845 | investorshub | 05/10/2023 6:49:32 PM |
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...